Detailed information for compound 2139868
Basic information
Technical information
- TDR Targets ID: 2139868
- Name: methyl (2S)-2-[[(2S)-2-[[2-[(2-aminoacetyl)am ino]acetyl]amino]-3-phenylpropanoyl]amino]-4- methylpentanoate
- MW: 406.222 | Formula: C20H30N4O5
-
H donors: 4
H acceptors: 4
LogP: 0.67
Rotable bonds: 15
Rule of 5 violations (Lipinski): 0 - SMILES: NCC(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)OC)CC(C)C)Cc1ccccc1
- InChi: InChI=1S/C20H30N4O5/c1-13(2)9-16(20(28)29-3)24-19(27)15(10-14-7-5-4-6-8-14)23-18(26)12-22-17(25)11-21/h4-8,13,15-16H,9-12,21H2,1-3H3,(H,22,25)(H,23,26)(H,24,27)/t15-,16-/m0/s1
- InChiKey: CSHFHJNMIMPJST-HOTGVXAUSA-N
Network
Hover on a compound node to display the structore
Synonyms
- methyl (2S)-2-[[(2S)-2-[[2-[(2-aminoacetyl)amino]acetyl]amino]-3-phenyl-propanoyl]amino]-4-methyl-pentanoate
- (2S)-2-[[(2S)-2-[[2-[(2-amino-1-oxoethyl)amino]-1-oxoethyl]amino]-1-oxo-3-phenylpropyl]amino]-4-methylpentanoic acid methyl ester
- (2S)-2-[[(2S)-2-[[2-(glycylamino)acetyl]amino]-3-phenyl-propanoyl]amino]-4-methyl-valeric acid methyl ester
- methyl (2S)-2-[[(2S)-2-[2-(2-aminoethanoylamino)ethanoylamino]-3-phenyl-propanoyl]amino]-4-methyl-pentanoate
Targets
Known targets for this compound
| Species | Target name | Source | Bibliographic reference |
|---|---|---|---|
| Ovis aries | Cyclooxygenase-1 | References | |
| Homo sapiens | prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) | References |
Predicted pathogen targets for this compound
By orthology
No druggable targets predicted by orthology data
By sequence similarity to non orthologous known druggable targets
No druggable targets predicted by sequence similarity
Obtained from network model
Ranking Plot
Putative Targets List
| Species | Potential target | Raw | Global | Species |
|---|---|---|---|---|
| Loa Loa (eye worm) | hypothetical protein | 0.0079 | 0.5 | 0.5 |
| Loa Loa (eye worm) | hypothetical protein | 0.0079 | 0.5 | 0.5 |
| Echinococcus multilocularis | peroxidasin | 0.0079 | 0.5 | 0.5 |
| Loa Loa (eye worm) | hypothetical protein | 0.0079 | 0.5 | 0.5 |
| Loa Loa (eye worm) | animal heme peroxidase | 0.0079 | 0.5 | 0.5 |
| Onchocerca volvulus | Peroxidase homolog | 0.0079 | 0.5 | 0.5 |
| Loa Loa (eye worm) | hypothetical protein | 0.0079 | 0.5 | 0.5 |
| Loa Loa (eye worm) | blistered cuticle protein 3 | 0.0079 | 0.5 | 0.5 |
| Onchocerca volvulus | Dual oxidase homolog | 0.0079 | 0.5 | 0.5 |
| Brugia malayi | Peroxidasin | 0.0079 | 0.5 | 0.5 |
| Schistosoma mansoni | peroxidasin | 0.0079 | 0.5 | 0.5 |
| Brugia malayi | Animal haem peroxidase family protein | 0.0079 | 0.5 | 0.5 |
| Brugia malayi | Animal haem peroxidase family protein | 0.0079 | 0.5 | 0.5 |
| Loa Loa (eye worm) | animal heme peroxidase | 0.0079 | 0.5 | 0.5 |
| Onchocerca volvulus | 0.0079 | 0.5 | 0.5 | |
| Onchocerca volvulus | Peroxidasin homolog | 0.0079 | 0.5 | 0.5 |
| Loa Loa (eye worm) | hypothetical protein | 0.0079 | 0.5 | 0.5 |
| Echinococcus granulosus | peroxidasin | 0.0079 | 0.5 | 0.5 |
| Schistosoma mansoni | peroxidasin | 0.0079 | 0.5 | 0.5 |
| Brugia malayi | Animal haem peroxidase family protein | 0.0079 | 0.5 | 0.5 |
| Loa Loa (eye worm) | hypothetical protein | 0.0079 | 0.5 | 0.5 |
| Brugia malayi | Animal haem peroxidase family protein | 0.0079 | 0.5 | 0.5 |
| Onchocerca volvulus | 0.0079 | 0.5 | 0.5 | |
| Loa Loa (eye worm) | animal heme peroxidase | 0.0079 | 0.5 | 0.5 |
| Loa Loa (eye worm) | hypothetical protein | 0.0079 | 0.5 | 0.5 |
| Loa Loa (eye worm) | hypothetical protein | 0.0079 | 0.5 | 0.5 |
| Onchocerca volvulus | Peroxidase homolog | 0.0079 | 0.5 | 0.5 |
| Onchocerca volvulus | Peroxidasin homolog | 0.0079 | 0.5 | 0.5 |
| Loa Loa (eye worm) | hypothetical protein | 0.0079 | 0.5 | 0.5 |
| Loa Loa (eye worm) | hypothetical protein | 0.0079 | 0.5 | 0.5 |
| Loa Loa (eye worm) | hypothetical protein | 0.0079 | 0.5 | 0.5 |
| Loa Loa (eye worm) | animal heme peroxidase | 0.0079 | 0.5 | 0.5 |
| Loa Loa (eye worm) | hypothetical protein | 0.0079 | 0.5 | 0.5 |
| Brugia malayi | Animal haem peroxidase family protein | 0.0079 | 0.5 | 0.5 |
| Loa Loa (eye worm) | hypothetical protein | 0.0079 | 0.5 | 0.5 |
| Onchocerca volvulus | Chorion peroxidase homolog | 0.0079 | 0.5 | 0.5 |
| Loa Loa (eye worm) | hypothetical protein | 0.0079 | 0.5 | 0.5 |
| Onchocerca volvulus | 0.0079 | 0.5 | 0.5 | |
| Brugia malayi | Blistered cuticle protein 3 | 0.0079 | 0.5 | 0.5 |
Activities
| Activity type | Activity value | Assay description | Source | Reference |
|---|---|---|---|---|
| Activity (functional) | Analgesic activity in Swiss albino mouse assessed as reduction in capsaicin-induced paw licking at 5 to 10 mg/kg, ip dosed 30 mins before capsaicin injection measured for 10 mins | ChEMBL. | 27019010 | |
| Activity (functional) | Analgesic activity in Swiss albino mouse assessed as reduction in capsaicin-induced paw licking at 5 to 10 mg/kg, ip dosed 30 mins before capsaicin injection measured for 10 mins in presence of ATP-sensitive potassium channel blocker glipizide pre-treated 30 mins before compound dosing | ChEMBL. | 27019010 | |
| Activity (functional) | Analgesic activity in Swiss albino mouse assessed as reduction in formalin-induced paw flinches in inflammatory phase at 5 mg/kg, ip dosed 30 mins before formalin injection measured after 15 to 30 mins | ChEMBL. | 27019010 | |
| Activity (functional) | Analgesic activity in Swiss albino mouse assessed as reduction in formalin-induced paw flinches in neurogenic phase at 5 mg/kg, ip dosed 30 mins before formalin injection measured up to 5 mins | ChEMBL. | 27019010 | |
| Activity (ADMET) | Acute toxicity in Swiss albino mouse assessed as structural abnormality in liver up to 2000 mg/kg, po administered as single dose through gavage measured after 14 days by haematoxylin and eosin staining based assay | ChEMBL. | 27019010 | |
| Activity (functional) | Analgesic activity in Swiss albino mouse assessed as reduction in capsaicin-induced paw licking at 5 to 10 mg/kg, ip dosed 30 mins before capsaicin injection measured for 10 mins in presence of voltage-gated sodium channel opener veratrine pre-treated 30 mins before compound dosing | ChEMBL. | 27019010 | |
| Activity (functional) | Analgesic activity in Swiss albino mouse assessed as reduction in capsaicin-induced paw licking at 5 to 10 mg/kg, ip dosed 30 mins before capsaicin injection measured for 10 mins in presence of nitric oxide precursor L-arginine pre-treated 30 mins before compound dosing | ChEMBL. | 27019010 | |
| Activity (functional) | Analgesic activity in Swiss albino mouse assessed as reduction in capsaicin-induced paw licking at 5 to 10 mg/kg, ip dosed 30 mins before capsaicin injection measured for 10 mins in presence of substance P pre-treated 30 mins before compound dosing | ChEMBL. | 27019010 | |
| Activity (functional) | Analgesic activity in Swiss albino mouse assessed as reduction in capsaicin-induced paw licking at 5 to 10 mg/kg, ip dosed 30 mins before capsaicin injection measured for 10 mins in presence of nitric oxide synthase inhibitor L-NAME pre-treated 30 mins before compound dosing | ChEMBL. | 27019010 | |
| Activity (ADMET) | Acute toxicity in Swiss albino mouse assessed as structural abnormality in myocardium up to 2000 mg/kg, po administered as single dose through gavage measured after 14 days by haematoxylin and eosin staining based assay | ChEMBL. | 27019010 | |
| Activity (ADMET) | Acute toxicity in Swiss albino mouse assessed as gross behavioral abnormality up to 2000 mg/kg, po administered as single dose through gavage measured continuously for first 4 hrs and periodically for 24 hrs up to 14 days | ChEMBL. | 27019010 | |
| Activity (functional) | Analgesic activity in Swiss albino mouse assessed as reduction in capsaicin-induced paw licking at 5 to 10 mg/kg, ip dosed 30 mins before capsaicin injection measured for 10 mins in presence of TxA2 stimulator A23187 pre-treated 30 mins before compound dosing | ChEMBL. | 27019010 | |
| Activity (binding) | = 0.08 ng/ml | Inhibition of COX2 in healthy human whole blood assessed as LPS-induced PGE2 level at 1 uM preincubated for 15 mins followed by LPS addition measured after 18 hrs by ELISA (Rvb = 15.5 ng/ml) | ChEMBL. | 27019010 |
| Activity (binding) | = 5.8 ng/ml | Inhibition of COX1 in healthy human whole blood assessed as calcium ionophore A23187-stimulated TXB2 level at 1 uM preincubated for 60 mins followed by A23187 addition measured after 30 mins by ELISA (Rvb = 8.5 ng/ml) | ChEMBL. | 27019010 |
| IC50 (binding) | = 0.06 uM | Inhibition of human recombinant COX2 assessed as reduction in PGH2-derived PGF2alpha using arachidonic acid as substrate preincubated for 10 mins followed by substrate addition measured after 2 mins by enzyme immunoassay | ChEMBL. | 27019010 |
| IC50 (binding) | = 6 uM | Inhibition of ovine COX1 assessed as reduction in PGH2-derived PGF2alpha using arachidonic acid as substrate preincubated for 10 mins followed by substrate addition measured after 2 mins by enzyme immunoassay | ChEMBL. | 27019010 |
| Inhibition (functional) | = 60 % | Antiinflammatory activity in Swiss albino mouse assessed as reduction in carrageenan-induced paw edema by measuring paw thickness at 5 mg/kg, ip dosed 30 mins before carrageenan injection measured up to 300 mins by vernier calliper method relative to control | ChEMBL. | 27019010 |
| Inhibition (functional) | = 80 % | Analgesic activity in Swiss albino mouse assessed as reduction in capsaicin-induced paw licking at 5 mg/kg, ip dosed 30 mins before capsaicin injection measured for 10 mins relative to control | ChEMBL. | 27019010 |
| Ka (binding) | = 0.41 10'3/M | Binding affinity to COX1 (unknown origin) at 100 uM by isothermal titration calorimetry | ChEMBL. | 27019010 |
| Ka (binding) | = 6.1 10'4/M | Binding affinity to COX2 (unknown origin) at 100 uM by isothermal titration calorimetry | ChEMBL. | 27019010 |
Phenotypes
Whole-cell/tissue/organism interactions
We have no records of whole-cell/tissue assays done with this compound
What does this mean?
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
Annotated phenotypes:
We have no manually annotated phenotypes for this drug.
What does this mean? / Care to help?
In TDR Targets, information about phenotypes that are caused by
drugs, or by genetic manipulation of cells (e.g. gene knockouts or
knockdowns) is manually curated from the literature. These
descriptions help to describe the potential of the target for drug
development. If no information is available for this gene or if the
information is incomplete, this may mean that i) the papers
containing this information either appeared after the curation
effort for this organism was carried out or they were inadvertently
missed by curators; or that ii) the curation effort for this
organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.
External resources for this compound
- ChEMBL: CHEMBL3809156
Bibliographic References
1 literature reference was collected for this gene.
If you have references for this compound, please enter them in a user comment (below) or Contact us.